What side effects are associated with this type of intervention?

The most common side effects of IL-17A inhibitors like Taltz include injection site reactions, upper respiratory infections, and headaches. Other treatments for Idiopathic Subglottic Stenosis, such as corticosteroids and surgical interventions, may have side effects like hoarseness, infection, and scarring. Patients should discuss these potential side effects with their healthcare provider to make an informed decision.

What prior FDA approvals exist?

There is no specific information provided about prior FDA approvals for the treatment of Idiopathic Subglottic Stenosis, particularly with drugs similar to Taltz (IL-17A inhibitors). Generally, treatments for this condition have focused on managing symptoms and reducing the need for invasive surgeries, but specific FDA-approved drugs targeting IL-17A for this condition are not mentioned.

What other types of research exist?

Currently, there are no specific alternatives to Taltz (IL-17A inhibition) mentioned for Idiopathic Subglottic Stenosis in the provided context. However, exploring other biologics targeting inflammatory pathways, such as IL-6 inhibitors, TNF-alpha inhibitors, or other cytokine modulators, might be potential alternatives. Consulting with a healthcare provider for the latest research and clinical trials is recommended.

← Back to Search

Monoclonal Antibodies

Taltz for Laryngostenosis

Phase 2

Waitlist Available

Led By Nwanmegha Young, MD

Research Sponsored by Yale University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

diagnosis of idiopathic subglottic stenosis

Diagnosis of idiopathic subglottic stenosis

Must not have

Disease involving the vocal cords

History of inflammatory bowel disease

Timeline

Screening 3 weeks

Treatment Varies

Follow Up every 8 weeks from baseline, up to 24 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing if Taltz can help patients with idiopathic subglottic stenosis by reducing inflammation and scar tissue in their airways. This could decrease their need for repeated surgeries.

Who is the study for?

This trial is for individuals with idiopathic subglottic stenosis, a narrowing of the airway below the vocal cords. Participants must consent to study procedures and be available throughout the study. It excludes those with tuberculosis history, pregnant or lactating women, people with inflammatory bowel disease, or allergies to Taltz.

What is being tested?

The trial tests if Taltz can inhibit IL-17A activation to reduce scar tissue growth in patients' airways, potentially decreasing the need for repeated surgeries.

What are the potential side effects?

Taltz may cause side effects such as injection site reactions (like redness), increased risk of infections due to immune system suppression, and possibly allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with idiopathic subglottic stenosis.

Select...

I have been diagnosed with idiopathic subglottic stenosis.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

My condition affects my vocal cords.

Select...

I have a history of inflammatory bowel disease.

Select...

I have had tuberculosis in the past.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ every 8 weeks from baseline, up to 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~every 8 weeks from baseline, up to 24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and every 8 weeks from baseline, up to 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in Airway, Dyspnea, Voice, and Swallowing (ADVS) Summary Assessment

Chronic Obstructive Airway Disease

Change in European Quality of Life-Five Dimensions (EQ-5D) Questionnaire

+6 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: TalzExperimental Treatment1 Intervention

All participants receive Talz

0 / 5Eligibility criteria met

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

The most common treatments for Idiopathic Subglottic Stenosis (iSGS) often involve managing inflammation and reducing scar tissue formation. One promising approach, as studied with the drug Taltz, involves inhibiting IL-17A activation. IL-17A is a cytokine that contributes to inflammation and the proliferation of scar fibroblasts. By inhibiting IL-17A, the treatment aims to reduce fibroblast activity, thereby decreasing scar tissue formation and the need for invasive surgeries. This targeted approach is significant for iSGS patients as it offers a potential reduction in airway obstructions and an improvement in overall quality of life.

Research advances in airway remodeling in asthma: a narrative review.Challenging the paradigm: moving from umbrella labels to treatable traits in airway disease.Effect of sublingual immunotherapy on antigen-induced bronchial and nasal inflammation in mice.